GSK (NYSE:GSK) Releases FY 2025 Earnings Guidance

GSK (NYSE:GSK) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 2.090-2.130 for the period, compared to the consensus EPS estimate of 4.520. The company issued revenue guidance of $40.1 billion-$40.9 billion, compared to the consensus revenue estimate of $34.3 billion.

Analyst Ratings Changes

GSK has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and decreased their target price for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, StockNews.com cut shares of GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 21st. Six analysts have rated the stock with a hold rating, one has given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Price Performance

GSK stock traded up $2.80 during trading hours on Wednesday, hitting $37.64. The stock had a trading volume of 8,298,732 shares, compared to its average volume of 4,446,791. GSK has a 1-year low of $31.72 and a 1-year high of $45.92. The stock has a market capitalization of $78.02 billion, a price-to-earnings ratio of 24.48, a PEG ratio of 1.38 and a beta of 0.64. The stock’s fifty day moving average is $34.10 and its two-hundred day moving average is $37.60. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

GSK (NYSE:GSK) last posted its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 50.62% and a net margin of 7.97%. As a group, analysts predict that GSK will post 3.92 earnings per share for the current fiscal year.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.